ArticleHuman vaccines & immunotherapeutics2025
Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial-temporal dynamics of HZ prevalence among high-risk groups: a global multiregional cohort analysis since 1990.Virology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339-1424) and median length of stay (4-5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 -16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.